HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis

References

• Dand N, Mahil SK, Capon F, et al. Psoriasis and genetics. Acta Derm Venereol. 2020 Jan 30;100(3):adv00030.
   PubMedGoogle Scholar
• Girolomoni G, Strohal R, Puig L, et al. The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol JEADV. 2017 Oct;31(10):1616–1626.
   PubMed Web of Science ®Google Scholar
• Villanova F, Flutter B, Tosi I, et al. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J Invest Dermatol. 2014 Apr;134(4):984–991.
   PubMed Web of Science ®Google Scholar
• Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Iimmunol. 2011 Jul 1;187(1):490–500. (Baltimore, Md: 1950).
   PubMed Web of Science ®Google Scholar
• Albanesi C, Madonna S, Gisondi P, et al. The interplay between keratinocytes and immune cells in the pathogenesis of psoriasis. Front Immunol. 2018;9:1549.
   PubMed Web of Science ®Google Scholar
• Karle A, Spindeldreher S, Kolbinger F. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. mAbs. 2016;8(3):536–550.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol JEADV. 2017 May;31(5):774–790.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Talamonti M, De Simone C. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Exp Opin Biol Ther. 2018 Jul;18(7):727–735.
   PubMed Web of Science ®Google Scholar
• Ovejero-Benito MC, Prieto-Perez R, Llamas-Velasco M, et al. Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis. Pharmacogenomics. 2018 Jan;19(1):7–16.
   PubMed Web of Science ®Google Scholar
• Prieto-Pérez R, Solano-López G, Cabaleiro T, et al. New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis. Pharmacogenomics J. 2018 Jan;18(1):70–75.
   PubMed Web of Science ®Google Scholar
• Talamonti M, Botti E, Galluzzo M, et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol. 2013 Aug;169(2):458–463.
   PubMed Web of Science ®Google Scholar
• Prieto-Pérez R, Llamas-Velasco M, Cabaleiro T, et al. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis. Pharmacogenomics. 2017 Jan;18(2):157–164.
   PubMed Web of Science ®Google Scholar
• Raposo I, Carvalho C, Bettencourt A, et al. Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab. Eur J Dermatol. 2017 Oct 1;27(5):528–530.
   PubMed Web of Science ®Google Scholar
• Masouri S, Stefanaki I, Ntritsos G, et al. A Pharmacogenetic study of psoriasis risk variants in a greek population and prediction of responses to anti-TNF-α and Anti-IL-12/23 agents. Mol Diagn Ther. 2016 Jun;20(3):221–225.
   PubMed Web of Science ®Google Scholar
• Dand N, Duckworth M, Baudry D, et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol. 2019 Jun;143(6):2120–2130.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Boca AN, Botti E, et al. IL12B (p40) gene polymorphisms contribute to ustekinumab response prediction in psoriasis. Dermatology. 2016;232(2):230–236.
   PubMed Web of Science ®Google Scholar
• Batalla A, Coto E, González-Fernández D, et al. The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients. Pharmacogenet Genomics. 2015 Jun;25(6):313–316.
   PubMed Web of Science ®Google Scholar
• van Vugt LJ, van den Reek J, Meulewaeter E, et al. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. J Eur Acad Dermatol Venereol JEADV. 2020 Jan;34(1):112–118.
   PubMed Web of Science ®Google Scholar
• Costanzo A, Bianchi L, Flori ML, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol. 2018 Nov;179(5):1072–1080.
   PubMed Web of Science ®Google Scholar
• Ahmed H, Yusuf N. Genetic influences on pharmacological interventions in psoriasis. J Clin Exp Dermatol Res. 2017;8:392–406.
   Google Scholar
• Tsoi LC, Spain SL, Knight J, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012 Dec;44(12):1341–1348.
   PubMed Web of Science ®Google Scholar
• Tsoi LC, Spain SL, Ellinghaus E, et al. Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci. Nat Commun. 2015 May 5;6:7001.
   PubMed Web of Science ®Google Scholar
• Tsoi LC, Stuart PE, Tian C, et al. Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. Nat Commun. 2017 May 24;8:15382.
   Google Scholar
• Ellinghaus E, Ellinghaus D, Stuart PE, et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet. 2010 Nov;42(11):991–995.
   PubMed Web of Science ®Google Scholar
• Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet. 2009 Feb;41(2):199–204.
   PubMed Web of Science ®Google Scholar
• Ryan C, Bowcock A, Menter A. Use of pharmacogenomics in psoriasis. Clin Invest. 2011;1:399.
   Google Scholar
• Stuart PE, Nair RP, Ellinghaus E, et al. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet. 2010 Nov;42(11):1000–1004.
   PubMed Web of Science ®Google Scholar
• Anderson MJ, Willis TJ. Canonical analysis of principal coordinates: a useful method of constrained ordination for ecology. Ecology. 2003;84:511–525.
   Web of Science ®Google Scholar
• Anderson MJ, Robinson J. Generalised discriminant analysis based on distances. Aust NZ J Stat. 2003;45:301–318.
   Web of Science ®Google Scholar
• Kisiel B, Kisiel K, Szymański K, et al. The association between 38 previously reported polymorphisms and psoriasis in a Polish population: high predicative accuracy of a genetic risk score combining 16 loci. PloS One. 2017;12(6):e0179348.
   PubMed Web of Science ®Google Scholar
• Feng BJ, Sun LD, Soltani-Arabshahi R, et al. Multiple Loci within the major histocompatibility complex confer risk of psoriasis. PLoS Genet. 2009 Aug;5(8):e1000606.
   PubMed Web of Science ®Google Scholar
• Strange A, Capon F, Spencer CC, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet. 2010 Nov;42(11):985–990.
   PubMed Web of Science ®Google Scholar
• Dand N, Mucha S, Tsoi LC, et al. Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling. Hum Mol Genet. 2017 Nov 1;26(21):4301–4313.
   PubMed Web of Science ®Google Scholar
• Capon F, Munro M, Barker J, et al. Searching for the major histocompatibility complex psoriasis susceptibility gene. J Invest Dermatol. 2002 May;118(5):745–751.
   PubMed Web of Science ®Google Scholar
• Clop A, Bertoni A, Spain SL, et al. An in-depth characterization of the major psoriasis susceptibility locus identifies candidate susceptibility alleles within an HLA-C enhancer element. PloS One. 2013;8(8):e71690.
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M. Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients. Br J Dermatol. 2017 Aug;177(2):489–496.
   Google Scholar
• Papini M, Cusano F, Romanelli M, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study. Br J Dermatol. 2019 Aug;181(2):413–414.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, D’Adamio S, Silvaggio D, et al. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Exp Opin Biol Ther. 2020 Feb;20(2):173–182.
   PubMed Web of Science ®Google Scholar
• Hundhausen C, Bertoni A, Mak RK, et al. Allele-specific cytokine responses at the HLA-C locus: implications for psoriasis. J Invest Dermatol. 2012 Mar;132(3 Pt 1):635–641.
   PubMed Web of Science ®Google Scholar
• Fagerberg L, Hallström BM, Oksvold P, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics. 2014 Feb;13(2):397–406.
   PubMed Web of Science ®Google Scholar
• Lande R, Botti E, Jandus C, et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014 Dec 3;5:5621.
   PubMed Web of Science ®Google Scholar
• Kimura K, Wakamatsu A, Suzuki Y, et al. Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes. Genome Res. 2006 Jan;16(1):55–65.
   PubMed Web of Science ®Google Scholar
• Steinle A, Li P, Morris DL, et al. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics. 2001 May-Jun;53(4):279–287.
   PubMed Web of Science ®Google Scholar
• Fania L, Morelli M, Scarponi C, et al. Paradoxical psoriasis induced by TNF-alpha blockade shows immunological features typical of the early phase of psoriasis development. J Pathol Clin Res. 2020 Jan;6(1):55–68.
   PubMedGoogle Scholar
• Zhu H, Lou F, Yin Q, et al. RIG-I antiviral signaling drives interleukin-23 production and psoriasis-like skin disease. EMBO Mol Med. 2017 May;9(5):589–604.
   PubMed Web of Science ®Google Scholar
• Ishizaki M, Akimoto T, Muromoto R, et al. Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo. J Iimmunol. 2011 Jul 1;187(1):181–189. (Baltimore, Md: 1950).
   PubMed Web of Science ®Google Scholar
• Chen L, Tsai TF. HLA-Cw6 and psoriasis. Br J Dermatol. 2018 Apr;178(4):854–862.
   PubMed Web of Science ®Google Scholar